Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02268682 · ClinicalTrials.gov registry record · NA

Explore Transplant at Home: Improving Low-Income ESRD Patients' Transplant Knowledge

A NA study of End Stage Renal Disease, sponsored by The Methodist Hospital Research Institute.

Completed
Registry status
NA
Development phase
558
Enrollment target
1
Study location

NCT02268682 is a NA study of End Stage Renal Disease that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 558 participants, below the 827-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02268682, a NA study of End Stage Renal Disease, has completed, sponsored by The Methodist Hospital Research Institute.

COMPLETED
Registry status
NA
Development phase
558 participants
Enrollment target
1
Study location

Study Summary

Kidney transplantation, especially living donor kidney transplant (LDKT), offers patients in end-stage renal disease (ESRD) 3 to 17 additional years of life and improved quality-of-life compared to remaining on dialysis. Unfortunately, LDKT education in dialysis centers occurs inconsistently, especially for minorities and those who are socioeconomically disadvantaged. To ensure more informed transplant decision-making, through a previous HRSA grant, Dr. Waterman designed the Explore Transplant (ET) education program based on the Transtheoretical Model of Behavioral Change. Through a previous trial, an earlier version of ET, delivered face-to-face with patients while they were undergoing dialysis, was shown to increase patients' DDKT and LDKT knowledge. However, additional research exploring dialysis providers' ability to integrate ET into their care revealed that multiple patient, provider, and system barriers limited the degree to which transplant education could be improved. Thus, a more comprehensive case-management program to educate patients through external organizations may be needed to supplement ongoing transplant education within dialysis centers. For this grant, the investigators propose to test the effectiveness of another replicable solution for disseminating ET education on a broad scale: Partnering with a large health insurance organization to deliver video-guided transplant education supported by telephone and mail. The Missouri Kidney Program (MoKP) is a state-wide organization whose mission is to serve and educate kidney patients, particularly those who are economically disadvantaged. Since MoKP subsidizes the costs of dialysis medication for low-income ESRD patients, they operate as an insurance company would with respect to their 1200-patient member group. With 900 dialysis patients currently being managed by the MoKP, the investigators will conduct an eight-month, group randomized controlled trial (GRCT) where 540 patients will be randomized t

Conditions Studied

Interventions

  • OTHER Patient-Guided
  • OTHER Educator-Guided

Study Locations (1)

California

  • UCLA Transplant Research and Education Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 558 participants
Start Date 2014-07
Est. Completion 2016-08
Phase NA

What the Registry Record Tells You About NCT02268682

The ClinicalTrials.gov registry entry for NCT02268682 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 827-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (33% lower). The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 2 interventions - of which Patient-Guided is the first listed.

NCT02268682 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02268682 about?

NCT02268682 is a clinical study titled "Explore Transplant at Home: Improving Low-Income ESRD Patients' Transplant Knowledge". Kidney transplantation, especially living donor kidney transplant (LDKT), offers patients in end-stage renal disease (ESRD) 3 to 17 additional years of life and improved quality-of-life compared to remaining on dialysis. Unfortunately, LDKT education in dialysis centers occurs inconsistently, especi...

What is the current status of trial NCT02268682?

This trial is currently completed. It is a NA study. The enrollment target is 558 participants. The study started on 2014-07. Estimated completion is 2016-08.

What conditions does trial NCT02268682 study?

This clinical trial studies the following conditions: End Stage Renal Disease.

What interventions are being tested in trial NCT02268682?

The interventions under investigation include: Patient-Guided (OTHER), Educator-Guided (OTHER).

Who is sponsoring clinical trial NCT02268682?

This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02268682 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.